Examination of utility of fulvestrant 500mg intended for climacteric junior line relapse breast cancer patient
Not Applicable
- Conditions
- ER-positive postmenopausal metastatic/inoperable breast cancer
- Registration Number
- JPRN-UMIN000012849
- Lead Sponsor
- JA Aichi Konan Kosei Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
1. Life threatening including 2.Inflammatory breast cancer 3. Allergy to fulvestrant. 4. Previous therapy by fulvestrant 5. Patients considered ineligible by the attending physician.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method